| Title: |
(PSY05) Exploring Mental Health-Related Outcomes in Children and Youth With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. |
| Authors: |
Villagrán, Daniela Castillo, Suntornlohanakul, Rabporn, Khan, Nusaybah, Rajapaksa, Sajith, Johnstone, Joley, Yeh, E. Ann |
| Source: |
International Journal of MS Care; 2024 Supplement, Vol. 26, p11-11, 1/3p |
| Subject Terms: |
MENTAL health, FATIGUE (Physiology), ANXIETY, CONFERENCES & conventions, MYELIN oligodendrocyte glycoprotein antibody-associated disease, CNS demyelinating autoimmune diseases, MENTAL depression, PSYCHOLOGY of the sick, ADOLESCENCE, CHILDREN |
| Geographic Terms: |
TENNESSEE |
| Abstract: |
BACKGROUND: Little is known about anxiety, depression, and fatigue in youth and children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). OBJECTIVES: To evaluate associations between disease course (monophasic vs relapsing) and anxiety, depression, and fatigue in children and youth with MOGAD and other monophasic acquired demyelinating syndromes (mono-ADSs). METHODS: Consecutive children diagnosed with MOGAD and other mono-ADSs who completed anxiety, depression, and fatigue questionnaires were identified from the Neuroinflammatory Registry at the Hospital for Sick Children in Toronto, Ontario, Canada (2012-2022). Demographics, disease characteristics, Expanded Disability Status Scale (EDSS) scores, and questionnaire results were included in the analysis. Anxiety scores were obtained using the Screen for Child Anxiety Related Disorders--Child Version, depression scores using the Center for Epidemiological Studies Depression Scale for Children, and fatigue scores using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale. RESULTS: Children with MOGAD (n = 72; female n = 43; median age, 12.6; IQR, 9.6-15.1; 47 [65%] monophasic, 25 [35%] relapsing) and mono- ADS (n = 70; female n = 32; median age, 13; IQR, 8.6-15.3) were included. There were no significant differences between the 2 monophasic cohorts (MOGAD vs mono-ADS) in anxiety, depression, and fatigue scores. Children with relapsing MOGAD had significantly higher fatigue (relapsing: median, 24; IQR, 16-33; monophasic: median, 16.5; IQR, 7.8-27; P = .023) and depression scores (relapsing: median, 11.5; IQR, 7.5-21.3; monophasic: median, 9; IQR, 5-14; P = .035) than patients with monophasic disease. Higher EDSS scores correlated with higher depression scores in the monophasic (τb = 0.197; P = .007) cohort, but no association was found with anxiety and fatigue scores. CONCLUSIONS: Children with relapsing MOGAD have distinct mental health when compared with children with a monophasic course, regardless of antibody status. This may be driven by disease activity or disability. Future studies will evaluate associations of these outcomes with structural brain and optic nerve metrics in this cohort. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of MS Care is the property of Consortium of Multiple Sclerosis Centers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
